Galmed Pharmaceuticals (GLMD) Profit After Tax (2013 - 2025)

Galmed Pharmaceuticals' Profit After Tax history runs 13 years deep, the most recent figure standing at -$4.8 million for Q4 2025.

• In Q4 2025, Profit After Tax rose 59.26% year-over-year to -$4.8 million; the TTM figure through Dec 2025 stood at $673000.0 (up 108.95% YoY), while the FY2025 annual figure was -$10.3 million, down 37.14% from the prior year.
• Profit After Tax was -$4.8 million for Q4 2025 at Galmed Pharmaceuticals, down from $1.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $8.9 million in Q1 2021 to a low of -$57.5 million in Q4 2021.
• Historically, Profit After Tax has averaged -$3.5 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 96.65% in 2022, then soared 514.09% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$57.5 million in 2021, then jumped by 42.43% to -$33.1 million in 2022, then jumped by 64.32% to -$11.8 million in 2023, then dropped by 0.14% to -$11.8 million in 2024, then jumped by 59.26% to -$4.8 million in 2025.
• The last three Profit After Tax figures came in at -$4.8 million (Q4 2025), $1.9 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.